Phaseline

Companies › Bausch & Lomb

Bausch & Lomb: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 4; Ophthalmology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Miebo (Perfluorohexyloctane Ophthalmic Solution)
Perfluorocarbon ocular surface protectant; creates hydrophobic barrier on cornea to reduce
–Phase 4Dry Eye–
BL1332 ophthalmic solution–Phase 1Ocular PainNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06565650Miebo (Perfluorohexyloctane Ophthalmic Solution)Phase 4Dry EyeOphthalmologyNov 2025
NCT06978244BL1332 ophthalmic solutionPhase 1Ocular PainOphthalmologyNov 2026

From the company's SEC filings

Cash of $513m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Glaukos Huons PolyActiva Taejoon Pharmaceutical Belite Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.